Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial

Inclusion Criteria:

* Subject diagnosed with colorectal cancer stages IIa-IIIc, confirmed by histopathological examination, according to CSCO guidelines for diagnosis and treatment of colorectal cancer.
* Subject suitable for receiving FOLFOX4 or mFOLFOX6 as adjuvant chemotherapy after radical resection of colorectal cancer, receiving each dose and cumulative dose of oxaliplatin are 85mg/m2 and ≥540 mg/m2 respectively.
* Subject with Karnofsky performance status scale (Schag et al.1984) index ≥60 points and an expected survival time ≥6 months.
* Subject over 18 years of age, men or women.
* Subject without severe damage of the heart, liver, kidney or hematopoietic system.

Exclusion Criteria:

* Subject with any grade of peripheral neuropathy.
* Subject who has ever received treatment of neurotoxic chemotherapeutics, such as oxaliplatin, cisplatin, taxanes, or vinca alkaloids.
* Subject who is receiving agents with potential preventive or therapeutic effects to neuropathy, such as duloxedine, carbamazepine, venlafaxine, gabapentin, pregabalin, phenytoin, valproate, milnacipran, or tricyclic antidepressant.
* Subject who is participating or have participated in other clinical trials.
* Subject with a family history of hereditary/familial neuropathy.
* Subject who cannot take drugs orally.
* Subject with mental illness who cannot cooperate.
* Pregnant or lactation period women.